隶属于 Tufts University
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1893
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- New research from Tufts University School of Medicine identifies two anti-lipid antibodies—αPA and αPS—that appear early in Lyme disease infection, potentially before standard tests turn positive. - The study, published in Infection and Immunity, analyzed blood samples from 199 Lyme disease patients and found these antibodies decline after successful treatment, unlike current antibody markers. - Elevated αPS levels were associated with persistent symptoms in post-treatment Lyme disease syndrome patients but were largely absent in other autoimmune and chronic illnesses. - Larger validation studies are underway, including a multi-institution trial following patients for up to 15 months after diagnosis, before these biomarkers can support clinical testing.
- TransCelerate BioPharma and Tufts Center for the Study of Drug Development published peer-reviewed research showing Phase III protocols now average 5.96 million data points, with nearly one-third being non-essential procedures. - The study identifies that non-core procedures contribute substantially to participant and site burden while adding operational complexity without advancing primary study objectives. - The research provides practical considerations for sponsors to modernize protocol design in alignment with ICH E6(R3) guidelines, promoting fit-for-purpose data collection to reduce unnecessary complexity. - TransCelerate's Optimizing Data Collection team is developing tools and frameworks to help R&D organizations assess the scientific, regulatory, and operational utility of collected data.
- The FDA authorized the Q-Collar brain protection device in 2021 despite internal reviewers flagging the supporting studies as "flawed" and failing to demonstrate concussion prevention. - An investigative report revealed that over 46,000 units of the $199 device have been sold to vulnerable populations including children as young as 13, despite inconclusive evidence of clinical benefit. - The Journal of Neurotrauma has issued expressions of concern for six publications linked to the Q-Collar's evidence base following discovery of duplicated and mathematically inconsistent data. - The FDA's own statistical reviewer had recommended against authorization, finding that key studies "failed to meet the specified endpoints."
- Clinical trial complexity has increased significantly since 2000, with phase 3 study data volume rising by over 50% and per-patient costs nearly doubling, creating urgent need for streamlined operations. - Nearly all clinical operations professionals (99%) report the need to unify disparate systems, with most organizations currently using 4-5 different applications that don't effectively communicate with each other. - Implementing unified clinical platforms could reduce the average 26-step clinical process to just 8 steps, dramatically improving trial speed, quality, and collaboration while reducing manual data management.
- The TAICHIKNEE trial, which assesses web-based Tai Chi for knee osteoarthritis, has updated its ethics and regulatory documentation after one year. - Researchers are comparing Tai Chi interventions to routine care for individuals with knee pain due to osteoarthritis. - The study aims to promote mind-body approaches for managing knee osteoarthritis across healthcare systems, potentially reducing reliance on pharmacological interventions. - Initial findings were presented at the NIH Pragmatic Trials Collaboratory’s 2024 Annual Steering Committee Meeting, highlighting the study's significance.
- Industry experts at the Outsourcing in Clinical Trials Conference highlight promising signs of recovery in biotech venture financing, while regulatory reforms and pricing policies pose significant challenges. - Clinical trial complexity and recruitment challenges are increasing, with experts noting longer trial durations and higher failure rates, particularly affecting rare disease research and specialty workforce areas. - Artificial Intelligence emerges as a crucial tool for stabilizing operations, with applications in patient recruitment, data analysis, and protocol optimization, driving demand for professionals with advanced analytical skills.
- A clinical trial demonstrated that dronabinol, a synthetic THC, significantly reduced agitation in Alzheimer's disease patients by 30%. - The study found dronabinol to be well-tolerated, without causing common adverse effects like delirium or seizures. - Researchers plan to conduct larger, longer-term studies to explore additional applications of medical cannabis in managing symptoms for patients and caregivers. - Agitation affects approximately 40% of Alzheimer's patients and is a primary reason for emergency department visits and long-term care admissions.
• Leading pathologists highlight critical challenges in distinguishing between HER2-low and HER2-negative breast cancer cases, raising concerns about treatment decisions worth $100,000 or more. • Current immunohistochemistry (IHC) testing, regulated as a stain rather than a diagnostic assay, lacks standardization across laboratories, potentially leading to inconsistent results affecting patient care. • Recent clinical trials, including DESTINY-Breast06, demonstrate the growing importance of precise HER2 testing as new targeted therapies emerge for HER2-low and ultralow breast cancer patients.
